11月20日，老百姓跌1.51%，成交额1.97亿元。两融数据显示，当日老百姓获融资买入额1714.83万元， 融资偿还1625.81万元，融资净买入89.02万元。截至11月20日，老百姓融资融券余额合计5.16亿元。 资料显示，老百姓大药房连锁股份有限公司位于湖南省长沙市开福区青竹湖路808号，成立日期2005年 12月1日，上市日期2015年4月23日，公司主营业务涉及药品及健康相关商品的零售连锁业务。主营业务 收入构成为：中西成药80.95%，非药品12.11%，中药6.94%。 融资方面，老百姓当日融资买入1714.83万元。当前融资余额5.15亿元，占流通市值的4.15%，融资余额 低于近一年40%分位水平，处于较低位。 截至10月31日，老百姓股东户数6.37万，较上期增加1.94%；人均流通股11921股，较上期减少1.90%。 2025年1月-9月，老百姓实现营业收入160.70亿元，同比减少1.00%；归母净利润5.29亿元，同比减少 16.11%。 融券方面，老百姓11月20日融券偿还1.39万股，融券卖出1.47万股，按当日收盘价计算，卖出金额24.01 万元；融券余量9.10万股，融 ...

Group 1: China Jushi (600176.SH) - The company achieved a revenue of 139.04 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 19.53% [6] - The net profit attributable to shareholders reached 25.68 billion yuan, up 67.51% year-on-year, with a non-recurring net profit of 26.12 billion yuan, increasing by 125.91% [6][9] - The company is expected to achieve net profits of 34.91 billion, 41.07 billion, and 46.48 billion yuan from 2025 to 2027, driven by the recovery of fiberglass prices and demand from various downstream sectors [9] Group 2: Transsion Holdings (688036.SH) - The company reported a revenue of 204.66 billion yuan in Q3 2025, a year-on-year increase of 22.60%, while the net profit attributable to shareholders was 9.35 billion yuan, down 11.06% year-on-year [11] - The company is expected to achieve revenues of 694.0 billion, 751.7 billion, and 871.6 billion yuan from 2025 to 2027, with net profits of 38.2 billion, 56.7 billion, and 70.8 billion yuan respectively [13] Group 3: Tonglian Precision (688210.SH) - The company reported a revenue of 2.4 billion yuan in Q3 2025, a year-on-year increase of 5.75%, while the net profit attributable to shareholders was 884,000 yuan, down 91.67% year-on-year [15] - The company is expected to achieve revenues of 11.4 billion, 15.5 billion, and 21.1 billion yuan from 2025 to 2027, with net profits of 1.0 billion, 1.9 billion, and 2.9 billion yuan respectively [17] Group 4: Topband Co., Ltd. (002139.SZ) - The company achieved a revenue of 26.9 billion yuan in Q3 2025, a slight increase of 0.1% year-on-year, while the net profit attributable to shareholders was 900 million yuan, down 44.7% year-on-year [18] - The company is expected to achieve net profits of 6.2 billion, 8.5 billion, and 10.8 billion yuan from 2025 to 2027 [19] Group 5: Inspur Information (000977.SZ) - The company reported a revenue of 1206.69 billion yuan in the first three quarters of 2025, a year-on-year increase of 45%, with a net profit of 14.82 billion yuan, up 15% year-on-year [25] - The company is expected to achieve net profits of 26.38 billion, 37.31 billion, and 47.77 billion yuan from 2025 to 2027 [26] Group 6: Benda Pharmaceutical (300558.SZ) - The company achieved a revenue of 27.17 billion yuan in the first three quarters of 2025, a year-on-year increase of 15.90%, while the net profit attributable to shareholders was 3.17 billion yuan, down 23.86% year-on-year [28] - The company is expected to achieve revenues of 35.50 billion, 43.71 billion, and 53.09 billion yuan from 2025 to 2027, with net profits of 5.73 billion, 7.21 billion, and 8.56 billion yuan respectively [29] Group 7: XWANDA (300207.SZ) - The company reported a revenue of 435.34 billion yuan in the first three quarters of 2025, a year-on-year increase of 13.73%, with a net profit of 14.05 billion yuan, up 15.94% year-on-year [35] - The company is expected to achieve net profits of 21.83 billion, 30.29 billion, and 40.31 billion yuan from 2025 to 2027 [37] Group 8: YH Technology (688080.SH) - The company achieved a revenue of 2 billion yuan in Q3 2025, a year-on-year increase of 34.5%, with a net profit of 400 million yuan, up 17.5% year-on-year [39] - The company is expected to achieve net profits of 1.5 billion, 2 billion, and 2.6 billion yuan from 2025 to 2027 [40] Group 9: Zhongji Xuchuang (300308.SZ) - The company reported a revenue of 102.2 billion yuan in Q3 2025, a year-on-year increase of 56.8%, with a net profit of 31.4 billion yuan, up 125% year-on-year [42] - The company is expected to achieve net profits of 107 billion, 205 billion, and 268 billion yuan from 2025 to 2027 [43] Group 10: Dongfang Tower (002545.SZ) - The company achieved a revenue of 33.92 billion yuan in the first three quarters of 2025, a year-on-year increase of 9.05%, with a net profit of 8.28 billion yuan, up 77.57% year-on-year [44] - The company is expected to achieve net profits of 12.68 billion, 14.46 billion, and 17.19 billion yuan from 2025 to 2027 [46]

Investment Rating - The investment rating for the company is "Buy" [5][3]. Core Insights - The company reported a revenue of 20.068 billion yuan for Q1-Q3 2025, representing a year-on-year increase of 1.71%, while the net profit attributable to shareholders was 1.081 billion yuan, up 25.97% year-on-year [1][5]. - The company has entered a phase of optimizing store layouts and focusing on direct franchise stores, with a total of 17,385 stores as of Q3 2025, including 7,029 franchise stores [2]. - The retail business gross margin increased to 37.70%, and the sales expense ratio improved to 21.78% [2]. Financial Performance Summary - For Q1-Q3 2025, the company achieved a revenue of 20.068 billion yuan, with a net profit of 1.081 billion yuan, and a net profit excluding non-recurring items of 1.073 billion yuan [1][5]. - The revenue from traditional Chinese and Western medicine was 15.451 billion yuan, with a gross margin of 30.12% [1]. - The company expects EPS of 1.06, 1.21, and 1.41 yuan for 2025, 2026, and 2027 respectively [3]. Store Expansion and Management - The company completed its cross-province expansion and is now focusing on increasing market share in existing provinces, with a net increase of 832 stores in Q1-Q3 2025 [2]. - The company has optimized its store network by closing 447 stores while opening 300 new self-built stores and adding 979 franchise stores [2]. Profitability and Efficiency - The company is benefiting from improved gross margins in non-pharmaceutical products, which increased to 45.62% [1]. - The digital transformation has enhanced operational efficiency, contributing to a competitive advantage [2]. Future Earnings Projections - The company is projected to have a revenue of 27.186 billion yuan in 2025, with a growth rate of 2.6% [4]. - The net profit attributable to shareholders is expected to reach 1.205 billion yuan in 2025, reflecting a growth rate of 31.7% [4].

Core Viewpoint - The company "老百姓" (Lao Bai Xing) has experienced fluctuations in stock performance and financial metrics, indicating a mixed outlook for its business operations and market position [1][2]. Group 1: Stock Performance - On November 4, the stock price of 老百姓 increased by 2.03%, reaching 17.10 CNY per share, with a trading volume of 120 million CNY and a turnover rate of 0.94%, resulting in a total market capitalization of 12.977 billion CNY [1]. - Year-to-date, the stock price has risen by 4.97%, with a 3.01% increase over the last five trading days, a 3.70% increase over the last 20 days, but a decline of 9.52% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, the company reported a revenue of 16.07 billion CNY, reflecting a year-on-year decrease of 1.00%, while the net profit attributable to shareholders was 529 million CNY, down 16.11% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 2.069 billion CNY, with 991 million CNY distributed over the past three years [2]. Group 3: Shareholder and Institutional Holdings - As of October 31, the number of shareholders for 老百姓 reached 63,700, an increase of 1.94% from the previous period, while the average circulating shares per person decreased by 1.90% to 11,921 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 7.7558 million shares, a decrease of 7.3246 million shares from the previous period [2].

Investment Rating - The report maintains a "Buy" rating for the company [10] Core Insights - The company has shown steady revenue growth with a slight increase in profitability. For the first three quarters of 2025, the company achieved a revenue of 17.286 billion yuan (+0.39%) and a net profit attributable to shareholders of 1.225 billion yuan (+10.27%) [4] - The retail business revenue slightly decreased by 1.02% to 15.029 billion yuan, while the franchise and distribution business saw a significant growth of 17.45% to 1.738 billion yuan [6] - The company is actively optimizing its store network and product structure, having opened 137 new stores and closed 440 stores in the first three quarters of 2025, resulting in a total of 14,666 stores [7] Financial Performance Summary - For the first three quarters of 2025, the gross margin was 40.40% (+0.01 percentage points), and the net profit margin was 7.08% (+0.63 percentage points) [5] - The company forecasts revenues of 25.309 billion, 27.880 billion, and 30.792 billion yuan for 2025, 2026, and 2027 respectively, with net profits of 1.682 billion, 1.937 billion, and 2.236 billion yuan [8][12] - The projected P/E ratios for 2025, 2026, and 2027 are 18, 16, and 14 respectively [10]

Investment Rating - The report maintains a rating of "Add" for the company [4] Core Insights - The company has shown steady performance with revenue growth of 0.39% and net profit growth of 10.27% year-on-year for the first three quarters of 2025 [1] - The strategic adjustments made in response to market conditions have led to improved profitability, with a gross margin of 40.41% and a net margin of 7.64% [7] - The company has optimized its store structure by closing 440 direct stores and opening only 137, while increasing franchise stores by 285, indicating a focus on quality and efficiency [7] - The forecast for net profit is expected to grow to 17.24 billion, 19.89 billion, and 22.82 billion for the years 2025, 2026, and 2027 respectively, with corresponding PE ratios of 18, 16, and 14 [7] Financial Performance - For the first three quarters of 2025, the company achieved total revenue of 172.86 billion and a net profit of 12.25 billion [1] - The revenue for Q3 alone was 55.64 billion, with a net profit of 3.45 billion, reflecting a year-on-year increase of 1.97% and 10.14% respectively [1] - The company’s total revenue is projected to reach 252.65 billion in 2025, with a year-on-year growth rate of 5% [3][9] - The operating profit is expected to grow to 2.51 billion in 2025, reflecting a 14% increase [3][9] Store and Business Structure - As of the third quarter of 2025, the company operates a total of 14,666 stores, including 4,097 franchise stores [7] - The retail business revenue slightly decreased by 1.02% to 150.29 billion, while franchise and distribution revenue increased by 17.45% to 17.38 billion [7] - The company’s product lines include traditional Chinese medicine, which faced a revenue decline of 1.24% to 16.30 billion [7] Profitability Metrics - The company’s gross margin has slightly increased by 0.02 percentage points to 40.41%, while the net margin improved by 0.68 percentage points to 7.64% [7] - The report indicates a stable control over operating expenses, with a sales expense ratio of 24.96%, down by 1.03 percentage points [7] Valuation Ratios - The current PE ratio is reported at 21.9, with projections showing a decrease to 17.9 by 2025 [10] - The PB ratio is currently at 3.2, expected to decline to 2.7 by 2025 [10]

Investment Rating - The report maintains a "Buy" rating for the company, anticipating a price increase of over 15% in the next 6-12 months [4]. Core Insights - The company reported a revenue of 17.29 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 0.39%. The net profit attributable to shareholders was 1.22 billion yuan, up 10.27% year-on-year [2]. - In Q3 2025, the company achieved a revenue of 5.56 billion yuan, a year-on-year increase of 1.97%, and a net profit of 340 million yuan, up 10.14% year-on-year [2][3]. - The company is experiencing a recovery in revenue growth, with a stable expansion pace, having opened 137 new stores and closed 440 stores in the first three quarters of 2025 [3]. - The company is focused on cost reduction and efficiency improvement, with a sales expense ratio of 25.4%, down 1.5 percentage points year-on-year [4]. Summary by Sections Performance Review - For the first three quarters of 2025, the company achieved a revenue of 17.29 billion yuan, a net profit of 1.22 billion yuan, and a non-recurring net profit of 1.19 billion yuan, with respective year-on-year growth rates of 0.39%, 10.27%, and 8.8% [2]. Operational Analysis - The company’s revenue in Q3 2025 was 5.56 billion yuan, showing a recovery from Q2's -1.4% year-on-year growth to +1.97% in Q3. The total number of stores reached 14,666, including 4,097 franchise stores [3]. Cost Management and Business Performance - The retail business generated 15.03 billion yuan in revenue, down 1.02% year-on-year, while the franchise and distribution business saw a revenue increase of 17.45% to approximately 1.74 billion yuan [4]. - The overall gross margin for the company was 40.41%, with a net profit margin of 7.64%, reflecting slight improvements year-on-year [4]. Profit Forecast and Valuation - The company is expected to achieve net profits of 1.70 billion yuan, 1.91 billion yuan, and 2.15 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 11%, 13%, and 12% [4].

证券代码：603233 证券简称：大参林 公告编号：2025-066 大参林医药集团股份有限公司 关于2025年第三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及相关要求，现将 大参林医药集团股份有限公司（以下简称"公司"）2025 年第三季度主要经营数 据披露如下： 一、报告期末主要经营数据 1、主要会计数据 单位：元 币种：人民币 | | | 本报告期 | | 年初至报告 | | | --- | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 比上年同 | 年初至报告期末 | 期末比上年 | | | | | 期增减变 | | 同期增减变 | | | | | 动幅度(%) | | 动幅度(%) | | | 营业收入 | 6,545,672,910.36 | 2.51 | 20,068,245,786.99 | | 1.71 | | 利润总额 | 398,306,009.89 | 43.05 | 1,522,1 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-103 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于2025年第三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主 板上市公司 2025 年第三季度报告披露工作的重要提醒》相关要求，现将益丰 大药房连锁股份有限公司（以下简称"公司"）2025 年第三季度主要经营数据披 露如下： 一、报告期末主要经营数据 | | | 幅度(%) | | | --- | --- | --- | --- | | 总资产 | 26,071,387,113.50 | 27,974,736,950.35 | -6.80 | | 归属于上市公司 | | | | | 股东的所有者权 | 11,177,628,791.76 | 10,725,687,023.42 | 4.21 | | 益 | | | | ...

证券代码：603883 证券简称：老百姓 公告编号：2025-061 老百姓大药房连锁股份有限公司 关于 2025 年第三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主板 上市公司2025年第三季度报告披露工作的重要提醒》等相关要求，现将老百姓大 药房连锁股份有限公司（以下简称"公司"）2025年第三季度主要经营数据披露 如下： 注："本报告期"指本季度初至本季度末3个月期间。 2、主营业务分行业、分产品、分地区情况（2025年1-9月） （1）主要业务分行业情况 一、报告期末主要经营数据 1、主要会计数据 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告 | | | --- | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 期末比上年 | | | | | 减变动幅度 | | 同期增减变 | | | | | (%) | | 动幅度(%) | ...